Trilaciclib

Phase 3

G1 Therapeutics, Inc. (GTHX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Aug '27

GTHXPhase 2

Trilaciclib Phase 2 Est. Readout

Trilaciclib• TNBC - Triple-Negative Breast Cancer36

Aug 2027~Confirmed

CT.gov

00%

Sep '26

GTHXPhase 2

Trilaciclib Phase 2 Est. Readout

Trilaciclib• TNBC - Triple-Negative Breast Cancer36

Sep 2026~Confirmed

CT.gov

00%

Competitive Landscape

1 competitor in TNBC - Triple-Negative Breast Cancer

View Full Landscape

Drug Information

Target Indication

TNBC - Triple-Negative Breast Cancer

Clinical Trial

NCT04799249

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Zinmyleo

Prevention of chemotherapy-induced myelosuppression when administered prior to platinum/etoposide- or topotecan-containing regimens for extensive-stage small cell lung cancer (ES-SCLC).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

GTHX

G1 Therapeutics, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

Trilaciclib, carboplatin, etoposide，or TopotecanPhase 3

Extensive-stage Small-cell Lung Cancer

G1T38Phase 2

Carcinoma, Non-Small-Cell Lung

CylophosphamidePhase 2

Triple Negative Breast Cancer

LurbinectedinPhase 2

Lung Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts